Table I.
Patient demographics and baseline characteristics.
| dTCApFs dose, mg/m2 | |||||
|---|---|---|---|---|---|
| Characteristics | 6 (n=3) | 12 (n=3) | 24 (n=3) | 48 (n=3) | 96 (n=5) |
| Age, years | |||||
| Median (range) | 63 (62–77) | 61 (58–62) | 65 (57–67) | 72 (51–94) | 64 (55–77) |
| Mean (SE) | 68 (5) | 67 (4) | 67 (2) | 72 (8) | 64 (9) |
| Sex, n (male/female) | 3/0 | 2/1 | 1/2 | 2/1 | 3/2 |
| Tumor type, n | |||||
| Colorectal | 3 | 2 | 0 | 2 | 1 |
| Pancreatic | 0 | 0 | 1 | 0 | 4 |
| Othera | 0 | 1 | 2 | 1 | 0 |
| Prior therapies, n | |||||
| Chemotherapy | 3 | 4 | 4 | 1 | 3 |
| Radiotherapy | 1 | 2 | 1 | 1 | 0 |
| Surgery | 2 | 2 | 1 | 1 | 2 |
| Treatment with biological agents | 0 | 0 | 1 | 0 | 0 |
| Treatment with small molecules, such as TKIs. | 0 | 0 | 0 | 1 | 0 |
a
Includes neoplasms in the small intestine, lung, liver, and spinal cord. SE, standard error; TKIs, tyrosine kinase inhibitors.